Urokinase
- Generic Name
- Urokinase
- Brand Names
- Kinlytic
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9039-53-6
- Unique Ingredient Identifier
- 83G67E21XI
- Background
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond.
Urokinase was granted FDA approval on 16 January 1978.
- Indication
In Canada, urokinase is indicated for lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.
- Associated Conditions
- Obstruction; Catheter, Infusion Catheter (Vascular), Pulmonary Embolism, Pulmonary Embolism Acute Massive, Thromboembolism of the Coronary Artery, Thromboembolism of the Graft, Thromboembolism of the Peripheral Artery
- Associated Therapies
- -
Urokinase Therapy in Patients With Diabetic Foot Syndrome
- Conditions
- Diabetic FootIschemiaArterial Occlusive Disease
- Interventions
- Procedure: standard therapyDrug: Urokinase
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 5
- Registration Number
- NCT00823225
- Locations
- 🇩🇪
Franziskus Krankenhaus, Berlin, Germany
🇩🇪Klinikum Dortmund Nord GmbH, Dortmund, Germany
🇩🇪Klinikum Karlsbad Langensteinbach, Karlsbad, Germany
12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2008-12-01
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 129
- Registration Number
- NCT00799968
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Tangshan Worker's Hospital, Hebei Medical University, Tangshan, Hebei, China
Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood
- Conditions
- EmpyemaPneumonia
- Interventions
- Drug: UrokinaseProcedure: Video-Assisted Thoracoscopic
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- Spanish Society of Pediatric Surgery
- Target Recruit Count
- 200
- Registration Number
- NCT00798278
- Locations
- 🇪🇸
Hospital Infantil La Paz, Madrid, Spain
🇪🇸Hospital de Donostia, San Sebastián, Donostia, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
Urokinase Therapy in Diabetic Foot Syndrome
- Conditions
- IschemiaDiabetic FootArterial Occlusive Disease
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2010-03-25
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 77
- Registration Number
- NCT00537498
- Locations
- 🇩🇪
Universitätsklinikum Carl Gustav Carus UniversitätsGefäßcentrum, Dresden, Germany
Dornase Alfa and Urokinase for Kids With Pleural Empyema
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2008-05-12
- Lead Sponsor
- Azienda Ospedaliera di Padova
- Target Recruit Count
- 94
- Registration Number
- NCT00502632
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
🇮🇹Ospedali Riuniti di Bergamo, Bergamo, Italy
🇮🇹Ospedale Bambino Gesu', Roma, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.